Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
royalties
Pharma
Zymeworks pivots to become 'royalty-driven' drugmaker
Having found success with its out-licensed cancer med Ziihera, Zymeworks will apply the framework for that drug to all its products going forward.
Fraiser Kansteiner
Nov 18, 2025 8:25am
Fierce Biotech
Anaptys plans to split into 2 businesses
Sep 30, 2025 9:35am
Theravance sells remaining Trelegy royalties to GSK for $225M
Jun 2, 2025 9:18am
In royalty dispute, UK appeals court sides with GSK over AZ
Feb 14, 2024 8:22am
Royalty Pharma strikes $150M Skytrofa royalty deal with Ascendis
Sep 6, 2023 11:28am
Arbitration win over J&J gives Alkermes a $425M boost
Jun 6, 2023 3:23pm
